Delaware’s Governance Lock-In: SB 21 Upheld, Moelis Vindicated — Founder Control Moves From Litigation Risk to Drafting Choice
The Delaware Supreme Court just changed the risk calculus Delaware has spent decades selling one product: a coherent, court-centered system for resolving corporate fights. The last few months show the state retooling that product for a founder-and-co...
The Delaware Supreme Court just changed the risk calculus
Delaware has spent decades selling one product: a coherent, court-centered system for resolving corporate fights. The last few months show the state retooling that product for a founder-and-controller era. On Feb. 27, 2026, the Delaware Supreme Court upheld the state’s 2025 corporate-law overhaul (SB 21), a statute that limits some shareholder lawsuits and bars certain challenges when a transaction is approved by an independent committee or a public shareholder vote. Weeks earlier, on Jan. 20, 2026, the same court sided with Ken Moelis in a dispute over a stockholder agreement, reversing a Chancery decision that had cast doubt on broad founder-control arrangements.
Put together, the message is not subtle. Delaware is narrowing the space where plaintiffs can convert governance grievances into fiduciary-duty claims, while simultaneously stabilizing contractual control mechanisms that sophisticated parties actually use. For lawyers who litigate deals, that is a doctrinal development. For lawyers who paper deals, it is something more important: a drafting roadmap with fewer judicial tripwires.
SB 21 is a procedural wall dressed up as a policy fix
SB 21’s significance is not that it “rebalances” Delaware law in the abstract. It is that it hard-codes outcomes that used to be contested through litigation. When a statute says certain challenges are barred if a transaction clears specified approval pathways, it is effectively telling plaintiffs’ firms: your leverage point is no longer the complaint; it is the process.
That matters because modern Delaware deal litigation has long been about sequencing. Plaintiffs sue early, seek expedited discovery, and try to create settlement value before closing. Defendants respond by building a record that supports business judgment review, often through independent committees and carefully framed disclosures. SB 21 pushes that logic further by giving those protective steps more teeth, not just as evidence, but as a gatekeeping mechanism.
Critics have labeled the law a “billionaire’s bill,” and the political economy is obvious: controllers and large investors want fewer fiduciary-duty suits that function as a tax on transactions. But practitioners should focus on the operational point. If the statute channels disputes into compliance with approval mechanics, then the real battleground becomes what “independent” means, what counts as a meaningful shareholder vote, and how courts will treat conflicts that are disclosed but still structurally coercive.
Moelis: founder-control agreements are back in the “contract” lane
The Moelis decision is equally instructive, even if Reuters described its practical impact as limited. The Delaware Supreme Court reversed a Chancery ruling that had raised doubts about broad founder-control agreements, holding the challenge was time-barred and that the earlier decision had overreached.
That combination—procedural dismissal plus a critique of overreach—reads like a warning to the trial court: do not treat every aggressive governance arrangement as an occasion to re-police the bargain. Delaware has always been comfortable with private ordering, but the last few years have seen more attempts to reframe contractual control as fiduciary breach. Moelis pushes the pendulum back toward enforcing the deal the parties signed, especially when plaintiffs wait too long to complain.
For sponsors and founders, the practical takeaway is straightforward: control provisions are more defensible when they are explicit, integrated into the company’s governing documents where required, and paired with a clear record of informed approval. For investors, the takeaway is less comforting: if you sign up for a governance structure that concentrates power, Delaware is signaling you may be stuck with it unless you can fit your grievance into a recognized contractual or statutory theory.
Advancement rights remain the exception that proves the rule
One reason Delaware can afford to tighten fiduciary-duty pathways is that it still polices certain corporate obligations with real intensity—especially advancement and indemnification. On July 2, 2026, a Delaware magistrate judge held JPMorgan could not stop paying Charlie Javice’s legal bills because the bank did not meet the high burden to show her requests were so unreasonable or abusive as to establish bad faith.
That is not a sideshow. Advancement disputes are often the first real test of whether a company’s bylaws and indemnification commitments mean what they say when the relationship collapses. The JPMorgan ruling reinforces a reality every GC and D&O broker already knows: advancement is intentionally company-friendly in drafting and executive-friendly in application. Courts presume the corporation promised broad coverage, and they require strong proof before letting a company cut off fees midstream.
In a world where SB 21 narrows some fiduciary-duty attacks, expect parties to fight harder over the contractual rights that remain—advancement, indemnification, forum selection, and information rights. Those are the pressure points that still generate leverage.
What changes in practice
1) Process becomes the product. If SB 21 blocks certain challenges after committee approval or a shareholder vote, then deal teams will treat process design as a form of litigation insurance. That means earlier committee formation, tighter minutes, more rigorous advisor conflicts checks, and more attention to the factual record that supports independence.
2) Governance agreements will get longer, not shorter. Moelis encourages parties to be explicit. Expect more detailed consent rights, more precise definitions of “control,” and more careful alignment between stockholder agreements and charter/bylaw provisions to avoid arguments that the parties exceeded statutory authority.
3) Plaintiffs will pivot theories. If fiduciary-duty routes narrow, plaintiffs will look harder at disclosure claims, contractual breaches, and statutory violations. They will also probe whether the committee was truly independent and whether the vote was structurally fair. SB 21 may reduce filings, but it will not eliminate conflict; it will relocate it.
4) Advancement disputes stay hot. The JPMorgan/Javice ruling is a reminder that Delaware still expects companies to pay first and argue later. Boards should assume advancement obligations will be enforced as written, and they should budget accordingly.
The bigger point
Delaware is not abandoning oversight; it is redefining where oversight lives. The state is steering disputes away from broad fiduciary-duty narratives and toward compliance with specified procedures and enforcement of negotiated rights. That is a coherent strategy for keeping Delaware attractive to controllers and dealmakers while preserving a role for courts.
But it comes with a cost. The more Delaware protects transactions from post-closing fiduciary attacks, the more it depends on the integrity of the approval process itself. If “independent committee” becomes a label rather than a reality, the doctrine will not save the system from cynicism—it will accelerate it.
Tags
Published by AnrakLegal AI